Evidence map›Paper›PMID 35395239›Full record

ArticleBiochemical pharmacology2022

Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A

Anna Vlachodimou, Henk de Vries, Milena Pasoli, Miranda Goudswaard, Soon-Ai Kim, Yong-Chul Kim, Mirko Scortichini, Melissa Marshall, Joel Linden, Laura H Heitman and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Applying Deep-Learning-DrivenJournal of medicinal chemistry · 2026
    Article
  2. Article
  3. APurinergic signalling · 2025
    Review
  4. ACS chemical biology · 2024
    Article
  5. Journal of medicinal chemistry · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Anna VlachodimouDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.
Henk de VriesDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.
Milena PasoliDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.
Miranda GoudswaardDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.
Soon-Ai KimLaboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Yong-Chul KimLaboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Mirko ScortichiniLaboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Melissa MarshallDepartment of Internal Medicine and Molecular Physiology & Biological Physics, University of Virginia Health Science Center, Charlottesville, VA 22908, USA.
Joel LindenDepartment of Internal Medicine and Molecular Physiology & Biological Physics, University of Virginia Health Science Center, Charlottesville, VA 22908, USA.
Laura H HeitmanDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands; Oncode Institute, Leiden, the Netherlands.
Kenneth A JacobsonLaboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: kennethj@niddk.nih.gov.
Adriaan P IJzermanDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands. Electronic address: ijzerman@lacdr.leidenuniv.nl.
Leiden University · NLNational Institute of Diabetes and Digestive and Kidney Diseases · USCentre for Human Drug Research · NLUniversity of Virginia · US

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Intramural NIH HHS ZIA DK031117
6 · The paper itself

Abstract

A

Indexed as

Purinergic P1 Receptor AntagonistsXanthinesAdenosine A2 Receptor AntagonistsKineticsRadioligand AssayReceptor, Adenosine A2BReceptors, Purinergic P1Adenosine A2 Receptor AntagonistsPurinergic P1 Receptor AntagonistsReceptor, Adenosine A2BReceptors, Purinergic P1XanthinesA(2B) adenosine receptorAntagonistsBinding kineticsCovalent bindingLabel-free functional assayRadioligand binding assay

Identifiers

PMID35395239
PMCPMC9358681
OpenAlexW4223425509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.